Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II

Cancer

Volumn 82, Issue 5, 1998, Pages 909-917

  Jungwirth, Andreas ^a,b   Schally, Andrew V ^a,b   Halmos, Gabor ^a,b   Groot, Kate ^a   Szepeshazi, Karoly ^a,b   Pinski, Jacek ^a,b   Armatis, Patricia ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer therapy; Bombesin antagonist; Luteinizing hormone releasing hormone antagonist; Renal cell carcinoma; Somatostatin analog

Indexed keywords

BOMBESIN ANTAGONIST; CETRORELIX; EPIDERMAL GROWTH FACTOR; GONADORELIN ANTAGONIST; RC 3940 II; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VAPREOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BOMBESIN; CARCINOMA, RENAL CELL; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; SOMATOSTATIN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032032276     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980301)82:5<909::AID-CNCR16>3.0.CO;2-4     Document Type: Article

References (40)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;44:5-27.
2. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996;335:865-75.
3. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303-21.
4. deKernion JB, Belldegrun A. Renal tumors. In: Campbell's urology. 6th edition. Philadelphia: W. B. Saunders, 1992:1053-93.
5. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res 1992;52:6074-78.
6. Takahashi A, Sasaki H, Kim SJ, Tobisu K-I, Kakizoe T, Tsukamoto T, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-37.
7. Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston WDW, Fair WR. Expression of transforming growth factor-α and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 1989;49:3407-11.
8. Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 1977;58:209-14.
9. Korhonen M, Sariola H, Gould VE, Kangas L, Virtanen I. Integrins and laminins in human renal carcinoma cells and tumors grown in nude mice. Cancer Res 1994;54:4532-8.
10. Luner SJ, Ghose T, Chatterjee S, Cruz HN, Belitsky P. Monoclonal antibodies to kidney and tumor-associated surface antigens of human renal cell carcinoma. Cancer Res 1986;46:5816-20.
11. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K-I, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6 receptor monoclonal antibody. Cancer Res 1995;55:590-6.
12. Cai RZ, Szoke B, Lu E, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A 1986;83:1896-1900.
13. Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, et al. Inhibition of growth of MKN45 gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer 1994;57:574-80.
14. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 1992;21:181-92.
15. Pinski J, Halmos G, Schally AV. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett 1993;71:189-96.
16. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977-85.
17. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E III, Bast RC Jr., Kufe DE, Morton DL, Weichselbaum RR, editors. Cancer medicine. 4th edition. Baltimore, MD: Williams and Wilkins, 1997:1067-86.
18. Reissman TH, Engel J, Kutscher B, Bernd M, Hilgard P, Peukert M, et al. Cetrorelix. Drugs Future 1994;19:228-37.
19. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A 1994;91:7090-4.
20. Cuttitta F, Carney DN, Mulshine J, Moody T, Fedorko J, Fisher A, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer cells. Nature 1985;316:823-6.
21. Qin Y, Ertl T, Cai RZ, Halmos G, Schally AV. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res 1994;54:1035-41.
22. Yano T, Pinski J, Groot K, Schally AV. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 1992;52:4545-7.
23. 2 showing high binding affinity to bombesin/GRP receptors on CFPAC-1 human pancreatic cancer cells. Int J Oncol 1995;6:1165-72.
24. Qin Y, Ertl T, Cai RZ, Horvath JE, Groot K, Schally AV. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Int J Cancer 1995;63:257-62.
25. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, et al. LH-RH antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen independent PC-3 prostate cancer in nude mice. Prostate 1997;32:164-72.
26. Breier BH, Gallaher BW, Gluckman PD. Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol 1991;128:347-57.
27. Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radiorecptor and radioimmunoassay of somatomedin in native and acid-ethanol extracted serum. J Clin Endocrinol Metab 1980;51:781-8.
28. Pinski J, Schally AV, Halmos G, Szepeshazi K. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate cancer xenografts in nude mice. Int J Cancer 1993;55:963-7.
29. Munson JP, Rodbard D. A versatile computerized approach for characterization of ligand binding systems. Anal Biochem 1980;107:220-39.
30. Szepeshazi K, Cai RZ, Radulovic S, Milovanovic S, Szoke B, Schally AV. Inhibitory effect of bombesin/GRP antagonist RC-3095 and high dose of somatostatin analog RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res 1991;51:5980-6.
31. Steel RGD, Torrie J. Principles and procedures of statistics. New York: McGraw-Hill, 1976.
32. Fisher DA, Salido EC, Barajas L. Epidermal growth factor and the kidney. Ann Rev Physiol 1989;51:67-80.
33. Derynck R, Goeddel DV, Ulrich A, Gutterman GU, Williams RD, Bringman TS, et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 1987;47:707-12.
34. Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor α, and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 1990;50:3834-9.
35. Freeman MR, Washecka R, Chung LWK. Aberrant expression of epidermal growth factor receptor and HER-2 (erb B-2) messenger RNAs in human renal cancers. Cancer Res 1989;49:6221-5.
36. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci U S A 1997;94:5810-3.
37. Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogs inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A 1989;86:2003-7.
38. Liebow C, Crean DH, Lee MT, Kramer AR, Mang TS, Schally AV. Synergistic effects of bombesin and epidermal growth factor on cancers may stimulate growth through up-regulation of EGF receptors. Proc Natl Acad Sci U S A 1994;91:3804-8.
39. Shirahige Y, Cook CB, Pinski J, Halmos G, Nair R, Schally AV. Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol 1994;5:1031-5.
40. Szepeshazi K, Schally AV, Cai R-Z, Halmos G, Groot K. Effects of new bombesin antagonists given singly or in combination with a somatostatin analog on nitrosamine-induced pancreatic cancers in hamsters. Int J Oncol 1996;9:397-403.